NCT06053983 is a Phase 4 clinical trial of Turbox CRP kit in Mi Q Wave, sponsored by Rawalpindi Medical College.

Who is sponsoring NCT06053983?

NCT06053983 is sponsored by Rawalpindi Medical College.

What drugs are being tested in NCT06053983?

Interventions in NCT06053983: Turbox CRP kit, rosuvastatin 20 mg,, atorvastatin 40 mg.

Is NCT06053983 still recruiting?

NCT06053983 is currently completed. Last updated 17 October 2023.

Last reviewed 2023-10-17 · How we verify

NCT06053983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

Completed Phase 4 Last updated 17 October 2023

What this trial tests

Phase 4 trial testing Turbox CRP kit in Mi Q Wave in 126 participants. Completed in 1 August 2023.

Timeline

1 January 2023

Primary endpoint
1 August 2023

1 August 2023

Quick facts

Lead sponsor	Rawalpindi Medical College
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	126
Start date	1 January 2023
Primary completion	1 August 2023
Estimated completion	1 August 2023
Sites	1 location across Pakistan

Drugs / interventions tested

Turbox CRP kit
rosuvastatin 20 mg,
atorvastatin 40 mg — full drug profile →

Conditions studied

Mi Q Wave — all drugs for Mi Q Wave →

Sponsor

Rawalpindi Medical College

Who can join

18 and older, any sex, with Mi Q Wave. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.
Khan S, Huda B, Bhurka F, Patnaik R, et al · · 2025 · cited 7× · PMID 40943351 · DOI 10.3390/ijms26178429

Verify or expand the search:

Other Rawalpindi Medical College trials

Trials by the same sponsor.

NCT07420127 — Comparison of Two Different Doses of Phenylephrine on Oxytocin Hemodynamic Effect · Phase 4 · recruiting
NCT07409688 — Pain Relief Following Laparoscopic Cholecystectomy While Comparing Intra Abdominal Versus Sub Cutaneous Local Anesthetic · Phase 4 · recruiting
NCT07088146 — Dexamethasone in Prolonging the Duration of Spinal Anesthesia Among Pregnant Patients · Phase 4 · recruiting
NCT07092943 — Driving Pressure Guided Mechanical Ventilation Versus Lung Protective Ventilation Among Patients Undergoing Elective Sur · NA · recruiting
NCT07078786 — Effect of Pre-delivery Dexamethasone in Comparison With Betamethasone on Fetal Heart Trace · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06053983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rawalpindi Medical College
Last refreshed: 17 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06053983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing